Searchable abstracts of presentations at key conferences in endocrinology

ea0002p40 | Endocrine tumours and neoplasia | SFE2001

Possible Functional Regression of Insulinoma with Prolonged Octreotide

Craig C , Gallen I

A 75 year old woman was treated for over three years with the somatostatin analogue, octreotide for insulinoma. She had presented in a hypoglycaemic coma. C-peptide and insulin levels were both raised. Cortisol, TSH, a gut hormone screen and urinary sulphonylurea levels were all normal. No adenoma was identified on CT or MRI scanning but angiography showed an area of increased vascularity within the pancreas. At laparotomy no lesion was found and no resection was undertaken. B...

ea0015p53 | Clinical practice/governance and case reports | SFEBES2008

Hypogonadotropic hypogonadism: a consequence of Chiari-I malformation

Kumar Sampath Satish , Chumas Paul , Peckham Daniel , Murray Robert

A 24-year-old women (wt 63 kg, BMI 23) presented with history of secondary amenorrhea. Menarche occurred at age 16 years and was followed by a regular cycle (7/35). She started the combined oral contraceptive pill (OCP) at 18 years of age for menorrhagia and stopped this 16 months before her presentation, before undergoing elective surgery. Four months after discontinuing the OCP she experienced a single episode of PV bleeding, but otherwise remained amenorrhoeic. Past history...

ea0005s4 | British Thyroid Association Pitt-Rivers Lecture | BES2003

The Na++/I- - symporter (NIS): Physiological and pathophysiological implications

Carrasco N , Dohan O , De|#Vieja A , Riedel C , Paroder V , Reed M , Smit J

The Na+/I- symporter (NIS) is a plasma membrane glycoprotein that mediates active I- transport in the thyroid follicular cells (the first step in thyroid hormone biosynthesis), and in other tissues, such as lactating mammary gland. NIS is the basis for the effective use of radioiodide in the diagnostic and treatment of thyroid cancer. NIS mutations hae been identified as causes of congenital iodide transport defect (ITD). We have isolated the cDNA that encodes NIS, generated h...

ea0056ep113 | Pituitary and Neuroendocrinology | ECE2018

Serum concentration of insulin-like growth factor I (IGF-I): reference values for adult Romanian population: Preliminary results

Alexandru Niculescu Dan , Dobre Ramona , Caragheorgheopol Andra , Popescu Nicoleta , Poiana Catalina

Background: Growth hormone, age, sex, genetics or nutrition status play an important role in insuline-like growth factor 1 (IGF-1) liver production and serum levels. Currently, there is no IGF-I reference range for Romanian population.Aim: To define sex- and age-adjusted reference values for serum IGF-I measured by an automated chemiluminescence immunoassay in adult Romanian population of healthy subjects.Methods: The study include...

ea0011p227 | Cytokines and growth factors | ECE2006

GH/IGF-I axis and haematological alterations in anorexia nervosa

Polli N , Cavagnini F

Anorexia nervosa (AN) is a psychiatric disorder featuring multiple endocrine abnormalities, comprising a decrease in IGF-I production and an increase in GH concentrations. This resistance to GH action may contribute to impaired haematopoiesis in AN as GH/IGF-I modulate blood cell proliferation and GH therapy exerts beneficial effects on hematocrit values in GH deficient patients. Aim of the present study is to evaluate the link between GH/IGF-I status and haematologic p...

ea0007p102 | Endocrine tumours and neoplasia | BES2004

IGF-I and IGFBP-3 mRNA expression in tamoxifen-resistant, recurrent breast cancers

McCarthy K , Laban C , McVittie C , Ogunkolade W , Khalaf S , Bustin S , Carpenter R , Jenkins P

IntroductionIncreased cross talk between the IGF-I and oestrogen signalling pathways has been implicated in the development of tamoxifen resistance in breast cancers. We have previously demonstrated IGF-I mRNA to be down-regulated in primary breast cancers. However, the expression of IGF-I and IGFBP-3 in recurrent, tamoxifen-resistant tumours is unknown.MethodsTotal RNA was extracted from 38 paired samples of...

ea0007p103 | Endocrine tumours and neoplasia | BES2004

IGF-I and IGFBP-3 mRNA expression in tamoxifen-resistant, recurrent breast cancers

McCarthy K , Laban C , McVittie C , Ogunkolade W , Khalaf S , Bustin S , Carpenter R , Jenkins P

IntroductionIncreased cross talk between the IGF-I and oestrogen signalling pathways has been implicated in the development of tamoxifen resistance in breast cancers. We have previously demonstrated IGF-I mRNA to be down-regulated in primary breast cancers. However, the expression of IGF-I and IGFBP-3 in recurrent, tamoxifen-resistant tumours is unknown.MethodsTotal RNA was extracted from 38 paired samples of primary breast cancers (T) and adjacent normal (N) tissue and from 1...

ea0004oc16 | Endocrine tumours and neoplasia | SFE2002

IGF-I prevents deoxycholic acid-induced apoptosis in HT29 colorectal cells

Khalaf S , Ogunkolade W , Davies D , Bustin S , Jenkins P

Background: The pro-proliferative and anti-apoptotic IGF-I is implicated in the development of colorectal cancer (CRC) in both the general population and patients with acromegaly. The local intracolonic environment is also likely to be important, particularly unconjugated bile acids such as deoxycholic acid (DCA). Whilst low faecal concentrations may be proliferative, high levels are toxic to colonic epithelial cells.High levels of DCA have been linked t...

ea0073aep319 | Diabetes, Obesity, Metabolism and Nutrition | ECE2021

Angiotensin-converting enzyme gene (i/d) polymorphism in association with the diabetic nephropathy

Hasan Taner , Trajkovska Ivana , Nedeska Natasha , Ilijevska Cvetanka Volkanovska , Josifovska Slavica

Polymorphisms in the Angiotensin-converting enzyme (ACE) gene have been associated with development of diabetic nephropathy (DN), a major microvascular complication of the type 2 diabetes mellitus (T2DM). Since the genetic predisposition plays an important role in development of DN in patients with T2DM, genetic testing might largely contribute to better assessment of the risk of DN in such patients. The aim of this study is to investigate the association of the ACE gene I/D p...

ea0044s1.1 | Challenges in pituitary disease | SFEBES2016

How to manage patients with acromegaly and discordant GH and IGF-I results

Trainer Peter

Serum GH and IGF-I levels are closely correlated but discordance between GH and IGF-I levels can occur in patients with acromegaly either as a consequence of biological factors or as an artefact of the means of assessment or definitions of normality.Pegvisomant as a GH receptor antagonist lowers serum IGF-I but, due to negative feedback, increases GH levels. Raloxifene has been shown to lower IGF-I in men and women with acromegaly and oestrogen has been ...